DENMEAD, England – April 23, 2012: Microsulis Medical Ltd, the specialist in microwave ablation, will host a satellite symposium entitled ‘2.45GHz microwave ablation: top tips to improve outcomes in the liver and lung’ at the European Conference on Interventional Oncology (ECIO) in Florence, Italy, this week.

 

Moderating the symposium will be Prof Thomas Helmberger from Klinikum Bogenhausen, Germany. Speaking will be Prof Philippe Pereira from SLK-Kliniken Heilbronn, Germany, and Dr David Breen from University Hospitals of Southampton, UK.

 

Prof Pereira will discuss his experiences using microwave ablation compared to Radiofrequency Ablation (RFA) and share current results in the lung, while Dr Breen will share ten top tips for optimising outcomes in microwave ablation of the liver.

 

The symposium takes place in the Main Auditorium, Palazzo dei Congressi, between 5.30pm and 6pm, on Wednesday April 25.  Find out more about the symposium and Microsulis’ devices at booth 5 in the exhibition hall.

 

Microsulis Medical's Acculis MTA system for the coagulation of soft tissue operates at 2.45GHz and is the most powerful device on the market when compared to Radio Frequency Ablation (RFA) devices and low power microwave systems.

 

 

Microsulis Medical is a specialist medical device company with market leading solutions in microwave ablation. The company’s products deliver significant technological and clinical advances to physicians and patients in minimally invasive, soft tissue ablation.  More information is available at www.microsulis.com.

 

The FDA has cleared the Acculis MTA system for the coagulation of soft tissue. The Acculis MTA system has not been cleared or approved for any specific treatments or therapies of a specific disease or condition that may be mentioned in this press release.